Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11529406 | 0.89 | NAALAD2 (0.50) | NAALAD2TBXAS1EGLN1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL31279551 | 0.87 | NAALAD2 (0.48) | NAALAD2TBXAS1EGLN1KDM4EALDH1A1 | |
| SCHEMBL3283757 | 0.86 | FFAR1 (0.46) | NAALAD2ACETBXAS1EGLN1ALDH1A1 | |
| SCHEMBL3281126 | 0.83 | L3MBTL1 (0.39) | NAALAD2TBXAS1ALDH1A1KMT2AMEN1 | |
| SCHEMBL3280409 | 0.83 | FFAR1 (0.60) | NAALAD2ACEEGLN1KDM4EKDM6B | |
| SCHEMBL3280282 | 0.82 | TDP1 (0.54) | TBXAS1ALDH1A1KMT2AMEN1ESR1 | |
| SCHEMBL8743365 | 0.82 | TBXAS1 (0.35) | NAALAD2ACETBXAS1ALDH1A1KMT2A | |
| SCHEMBL1833933 | 0.80 | TDP1 (0.62) | NAALAD2TBXAS1ALDH1A1KMT2AMEN1 | |
| SCHEMBL1831810 | 0.80 | TDP1 (0.62) | NAALAD2TBXAS1ALDH1A1KMT2AMEN1 | |
| SCHEMBL31565174 | 0.80 | NAALAD2 (0.43) | NAALAD2TBXAS1EGLN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304093-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | claimed |
| CN-1962596-A | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS INC (US) | 2007-05-16 | — | — | CN | claimed |
| EP-1564200-A1 | Ketone compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| CN-1479712-A | Ketone compounds and compositions for cholesterol management and related uses | ͨ��ҽ�ƹ�˾ | 2004-03-03 | — | — | CN | claimed |
| US-20030078239-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-04-24 | — | — | US | claimed |
| US-8975300-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975300-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140228439-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228439-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8642653-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642653-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
| CN-1962596-A | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS INC (US) | 2007-05-16 | — | — | CN | disclosed |
| CN-1283610-C | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS INC (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1701931-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1564200-A1 | Ketone compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005068412-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-6699910-B2 | TREATING AND PREVENTING CARDIOVASCULAR DISEASES, DYSLIPIDEMIAS, AND GLUCOSE METABOLISM AS HYPOGLYCEMIC AGENTS, USE TO REDUCE THE FAT CONTENT OF MEAT IN LIVESTOCK AND REDUCE THE CHOLESTEROL CONTENT OF EGGS | ESPERION THERAPEUTICS, INC. | 2004-03-02 | — | — | US | disclosed |
| WO-2002030860-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, CETP | NAALAD2 3800/4885ACE 327/4885TBXAS1 645/4885 |
| US-20140228439-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | NAALAD2 3829/4885ACE 327/4885TBXAS1 673/4885 |
| US-20030078239-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | NAALAD2 3829/4885ACE 327/4885TBXAS1 673/4885 |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | NAALAD2 3829/4885ACE 327/4885TBXAS1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.